Inhaler

Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for its once-daily Stiolto Respimat (tiotropium bromide and olodaterol) inhalation spray.

The FDA granted the approval for Stiolto Respimat as a long-term and once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Marketed as Stiolto Respimat, olodaterol is a long-acting beta2-agonist that has been specifically designed to complement the efficacy of Spiriva, which is the most prescribed COPD maintenance treatment worldwide.

Stiolta is administered through Respimat, the propellant-free, platform inhaler for Boehringer Ingelheim’s respiratory therapies, including approved and investigational therapies.

"Stiolto Respimat provides even further benefits than Spiriva alone and will offer a valuable new treatment option for patients and physicians."

Boehringer Ingelheim chief medical officer Dr Klaus Dugi said: "The approval of Stiolto Respimat in the US marks an important milestone in our ongoing commitment to provide effective solutions for patients with COPD.

See Also:

"Building on years of trusted experience with Spiriva, Stiolto Respimat provides even further benefits than Spiriva alone and will offer a valuable new treatment option for patients and physicians."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The approval was based on data from the pivotal Phase III Tonado I&II trials (NCT01431274/NCT01431287), which assessed more than 5,000 COPD patients.

The trials demonstrated that the drug provides statistically significant improvements in lung function over tiotropium and olodaterol alone.

Conducted as part of the TOviTO clinical trial programme that involved around 15,000 COPD patients across the globe, the trials demonstrated that Stiolto Respimat has a safety profile similar to tiotropium or olodaterol alone.

Image: Stiolto Respimat inhalation spray. Photo: courtesy of PRNewswire/Boehringer Ingelheim Pharmaceuticals, Inc.